Spectra Pharmaceutical ServicesInc said current clinical studies of its proposed dry eye drugTretinoin have not produced encouraging results based onpreliminary indications.    The compnay said the tests are being conducted forsubmission to the Food and Drug Administration for the drugwhich has the trade name Lacramore.    Spectra said earlier studies showing dramatic improvementsin isolated cases have still occurred. However, the overallevaluation of a large number of patients with dry eye syndromedo not demonstrate consistantly beneficial results, it added.    Spectra said it will continue its current studies, while atthe same time undertaking a review of the feasability of theproposed product    Spectra, a development stage company, also said it hasintroduced its first proprietary product, a hyo-allergenicnoniirritating cleanser for the cleaning of eyelids andeyelashes.    The company said it has also begun marketing a line ofophthalmic drugs. Reuter&#3;